Pipeline

March 15, 2020
Company Drug/Device Medical Condition Status
Debiopharm Debio 0123 refractory solid tumors that have recurred or progressed following prior platinum-based chemotherapy and for which no standard treatment is available initiation of phase 1 trial
FSD Pharma Ultra Micro-Plmitolylethanolamide (PEA) inflammatory conditions initiation of phase 1 trial
Virometix V-306 vaccine respiratory syncytial virus initiation of phase 1 trial
Actinium Pharma Actimab-A CLAG-M combination relapsed or refractory acute myeloid leukemia first patient treated in third and final cohort of phase 1 trial
Innate Pharma

AstraZeneca		 IPH5201 alone and in combination with durvalumab with or without oleclumab advanced solid tumors first patient dosed in phase 1 trial
Medivir AB MIV-818 advanced liver cancer first patient dosed in phase 1b study
InMed Pharma INM-755 epidermolysis bullosa and potentially other dermatological diseases patient enrollment complete in phase 1 study
Albireo elobixibat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease patient enrollment complete in phase 2 study
Tenax Therapeutics levosimendan pulmonary hypertension and heart failure with preserved ejection fraction patient enrollment complete in phase 2 study
Palvella Therapeutics PTX-022 (QTORIN 3.9% rapamycin anhydrous gel) Pachyonychia Congenita patient enrollment complete in phase 2/3 study
QED Therapeutics infigratinib adjuvant treatment of invasive urothelial carcinoma first patient dosed in phase 3 trial
ARVOBIO AVR-RD-04 gene therapy cystinosis Orphan Drug designation granted by FDA
TG Therapeutics umbralisib follicular lymphoma Orphan Drug designation granted by FDA
Spero Therapeutics oral SPR720 nontuberculous mycobacterial infection Orphan Drug designation granted by FDA
Janssen JNJ-6372 metastatic non-small cell lung cancer with EGFR Exon 20 insertion mutations where the disease has progressed while the patient is on or after receiving platinum-based chemotherapy Breakthrough Therapy designation granted by FDA
Neuronetics NeuroStar Advanced Therapy System bipolar depression Breakthrough Device designation granted by FDA
Aerin Medical RhinAer Stylus chronic rhinitis approved by the FDA
Allergan Durysta (bimatoprost implant) open-angle glaucoma or ocular hypertension approved by the FDA
AltaThera Pharmaceuticals Sotalol IV atrial fibrillation new indications approved by the FDA
Boehringer-Ingelheim Ofev (nintedanib) chronic fibrosing interstitial lung diseases with a progressive phenotype approved by the FDA
Bristol-Myers Squibb Opdivo (nivolumab) and Yervoy (ipilimumab) hepatocellular carcinoma which has been previously treated with Bayer’s Nexavar (sorafenib) approved by the FDA
Recordati Isturisa (osilodrostat) Cushing's disease when pituitary surgery is not an option or has not been curative approved by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here